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ABSTRACT 
Background and aim 
The concept of depression as a risk factor for cardiovascular diseases (CVD) is now 
well known. However, weather the severity of depression has a dose response effect 
on risk of CVD is not known. Also the role of risk factors which might be shared 
between depression and CVD, their interaction with depression and the combined 
effect on risk of CVD is still not well understood. For example, high level neuroticism 
is a risk factor for depression but also for CVD, but the combined effect of 
depression and high-level neuroticism on risk of CVD is not known. Likewise having 
comorbid conditions is linked to both depression and CVD, but the combined effect 
of depression and certain non-cardiovascular morbid conditions on risk of CVD is not 
known. The role of certain specific genotypes like Catechol-O methyltransferase 
(COMT) genotype and depression on risk of CVD is also less studied.  
The main aim of this PhD thesis is to increase the knowledge on the association 
between depression and cardiovascular diseases. 
Methods and Results 
For the purpose of this thesis I used the PART study (acronym in Swedish for: 
Psykisk hälsa, Arbete och RelaTioner, In English: Physical Health, Work and 
Relations), a longitudinal study of mental health, work and relations among adults > 
20 years of age residing in Stockholm County, Sweden. The study included three 
data collections, wave 1 (W1) in 1998–2000, wave 2 (W2) in 2001–2003 and wave 3 
(W3) in 2010. In total 10,443 individuals were included. Depression was assessed 
using the Major Depression Inventory (MDI). Severity of depression was assessed 
using MDI and additionally measuring anxious distress according to DSM-5 (paper 
I). Neuroticism was assessed by the Swedish Scale of Personality (SSP) for paper II. 
COMT genotype was measured using saliva from a subsample of the participants 
(paper III). Non-cardiovascular morbidity was assessed by asking current status of 
non-cardiovascular morbid conditions (paper IV). All participants from W1 were 
followed for cardiovascular outcomes through the National Patient register. For study 
III on genotype all participants from W1 were invited to contribute saliva for DNA 
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analysis, but only 4349 participated. Logistic regression and Cox regression was 
used to estimate the risk of CVD. 
In study I, I found that depression increased the risk of CVD at different severity 
levels of depression, and the highest risk was for those suffering from moderate 
depression. The increased risk was present for both ischemic heart disease and 
stroke. Also, those who suffered from depression with anxious distress were at 
higher risk for CVD. 
In study II on depression, neuroticism and CVD, I found that those who were 
depressed and had high level neuroticism were at increased risk of CVD than those 
depressed with low level of neuroticism. The interaction effect was confirmed by a 
synergy index > 1. 
In study III, the genetic study on the subsample of the PART, I found that those who 
were depressed and had a high activity COMT Val158Met genotype were at 
increased risk of CVD compared to those depressed with low activity COMT 
Val158Met. 
In Study IV, those who had depression and non-cardiovascular morbidity were at 
increased risk for CVD compared to those depressed with no non-cardiovascular 
morbidity. This risk was present also after accounting for age, gender, 
socioeconomic status and lifestyle factors. The interaction effect was confirmed by 
synergy index > 1. 
Conclusion  
This thesis has overall increased the knowledge on the association between 
depression and CVD. It further elaborated and created new knowledge on the effect 
of other factors like personality trait neuroticism, genes and non-cardiovascular 
morbid   conditions on the association between depression and CVD. More studies 
are required to confirm the biological mechanism in this relation and also design 
interventions to timely treat depression and other related factors to counter the risk of 
CVD. 
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1 BACKGROUND 
Depressive disorders are substantial cause of non-fatal burden of diseases (1). 
Major depression results when depressive moods turn into a chronic, incapacitating 
disorder interfering with daily life (2). The life-time prevalence of depression 
worldwide has been reported to vary between 8-12% and about eighty percent 
have recurrent episodes (3-5). Depression has multiple risk factors including 
genetics, physical, social and environmental ones (5, 6). 
Cardiovascular diseases (CVD) tops the list of the five leading causes of death 
globally during the last decade (7). Ischaemic heart disease and cerebrovascular 
disease are jointly responsible for more than 85.1% of all cardiovascular disease 
deaths in 2016 (8). Globally, deaths from CVD increased by 14.5% between 2006 to 
2016 (7). Established risk factors for CVD are high cholesterol, smoking, 
hypertension, diabetes, abdominal obesity, psychosocial issues, low consumption of 
fruits and vegetables, hazardous alcohol intake, family history of CVD and lack of 
physical activity (9). 
CVD being the leading cause of death today and depressive disorders being the 
major cause of non-fatal burden of diseases are of great public health significance. 
Furthermore, there is evidence that CVD events often are followed by depressive 
symptoms and that depression is a risk factor for CVD (10, 11). There is emphasis 
on promoting healthy lifestyle, control of hypertension, diabetes and dyslipidaemia 
for prevention of CVD both in clinical and public health settings (12-14). However, 
the concept of focusing on treating depression as a contributor to future CVD is 
relatively less established. Physicians and cardiologist in general primarily focus on 
controlling established modifiable risk factors and pay less attention to treatment of 
depression. The reasons for this disconnect in evidence and practise might be 
several. Firstly, data on severity of depressive disorders including depression in 
relation to CVD is lacking. Secondly, shared risk factors and mediators between 
depression and CVD are not very well studied. There might be some genetic, social, 
physical or environmental risk factors that are shared between depression and CVD. 
Thirdly, intervention studies incorporating treatment of depression, in addition to 
established modifiable risk factors, as intervention to reduce risk of CVD are few and 
in the initial phase (15).  
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1.1 DEPRESSIVE DISORDERS  
Depressive disorders include disruptive mood disturbance disorder, major 
depression , persistent depressive disorder , premenstrual dysphoric disorder, 
substance/medication-induced depressive disorder, depressive disorder due to 
another medical condition, other specified depressive disorder, and unspecified 
depressive disorder (16). These disorders differ in duration, timing, and presumed 
aetiology. 
1.1.1 Major depression  
Major depression (or shortly termed as depression) is defined as distinct episodes 
of at least two weeks’ duration (although most episodes last  longer) involving clear-
cut changes in affect, cognition, and neuro-vegetative functions and inter-episode 
remissions (17, 18). The mood changes of depression are due to a functional 
deficiency of the brain monoaminergic transmitters including norepinephrine, 
5/hydroxy tryptamine and/or dopamine. This is also referred to as the Monoamine 
hypothesis.(19) Prevalence rates for single lifetime episode of major depression 
has been estimated to 6.4% (20). I will be referring major depression as depression 
in the subsequent text for ease of understanding.  
Depression is known as a cause of increased morbidity and has been associated 
with high health care expenditure, adverse health outcomes, significant functional 
disability, reduced work capacity and productivity, occupational disability and 
incident organic  disease development (2). Despite these consequences of 
depression and available effective treatments, a majority of those depressed 
remain untreated (21). Untreated depression is associated with financial barriers, 
male gender, ethnic minority and both young and old ages (22-25). 
1.2 ASSESMENT OF DEPRESSION  
According to Diagnostic and statistical manual of mental health-IV(DSM-IV )and 
International classification of diseases (ICD-10), five of the following symptoms 
should  be present when making a  diagnosis of  depression; depressed mood, 
diminished interest in surroundings , loss of pleasure in all or almost all activities, 
weight loss or gain , insomnia or hypersomnia, psychomotor agitation or retardation, 
fatigue, feelings of worthlessness or inappropriate guilt, reduced ability to 
concentrate, recurrent thoughts of death or suicide (26, 27). At least one of the 
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symptoms must be either depressed mood, diminished interest or loss of pleasure. 
The symptom should last at least 2 weeks. 
1.2.1 Scales for assessing depression  
Choosing the right tool for assessing depression is essential when conducting 
studies to assess depression on population-based samples. The tools used in 
general are self-rating scales (screening tools and diagnostic tools) and the gold 
standard is always in-depth interview (structured or semi structured) by an 
experienced mental health clinician (28). Self-rating scales are cheaper and 
therefore are more widely used (29) but tend to be less sensitive in capturing 
changes in depressive symptoms over time (30).The sensitivity and specificity to 
diagnose depression for the self-rating scales has been estimated to 94 %(31). 
Clinically administered tools, on the other hand, are costly, requires additional 
requirements on clinicians' training and consultation times (32) but clinician 
administered scales are more sensitive to record change in depressive symptoms 
over time (30). 
 
The list of instruments available to assess depression is quite exhaustive. Most time 
tested  self-rating tool for assessment of depression in general populations is Beck 
Depression Inventory (BDI) (33). The most seasoned  clinician administered tool for 
measuring depression is the Hamilton Depression Rating Scale (34). An important 
two-step instrument to screen and diagnose depression in primary care is the self-
administered Patient Health Questionnaire (PHQ) (35).  
 
BDI is a 21 item self-rating scale, based on DSM III(33) This scale was designed to 
measure the severity of depressive symptoms that a person is experiencing “at that 
moment“. The BDI has undergone amendments and the latest one is the BDI II (36). 
However the clinical usefulness of the BDI when covering the DSM-IV symptoms of 
depression is limited (37). As a result the Major Depression Inventory (MDI), a self-
rating scale, was developed by Beck covering both International Classification of 
Diseases and Related Health Problems and 10th Revision (ICD-10). It was based on 
the nine DSM-IV symptoms and with marking points from 0 (not present) to 4 
(severely present). I will focus on MDI, since studies based in this thesis is based on 
a population-based sample. 
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1.3 SEVERITY OF DEPRESSION 
The severity of depression, predicts short-term treatment outcomes, probability of 
recovery, and response to pharmacological treatment (38-40). Severity of 
depression is measured based on number of symptoms over a 2 weeks period 
irrespective of the wellbeing or functional impairment.(41, 42) Alternative way of 
assessing severity of depression is using a categorisation from mild to severe 
depression. Mild depression is symptoms of depression resulting in only slight 
functional impairment. Moderate depression is symptoms with functional impairment 
between 'mild' and 'severe'. Severe depression is symptoms which markedly 
interferes with routine functioning. It may occur with or without psychotic symptoms 
(43). Some studies have assessed severity of depression in terms of psychosocial 
functioning and quality of life (44). 
In this thesis the former criteria for assessment of depression severity based on 
number of symptoms was used. The reason for this is that it is more practical to 
measure in this way in a large population-based samples and also since it can be 
self-administered. 
Commonly used scales used to assess depression severity include PHQ‐9 (45), 
Hospital Anxiety and Depression Scale (HADS-D)(46) and Hamilton Depression 
Rating Scale. However, all of these are used in primary care or hospital settings. 
Overall Depression Severity and Impairment Scale is a 5-item, continuous measure, 
developed to assess severity of mood disorders and with sub-threshold depressive 
symptoms (47). However this is more adapted to measure changes in depression 
status rather than diagnosis. BDI also discusses about severity of depression and 
categorizes it to mild, moderate and severe depression based on the total scores 
(48). ICD-10 criteria for diagnosing depression categorizes severity of depression 
into mild, moderate and severe depression.(26) MDI is a validated diagnostic tool for 
assessing depression, which also measures severity of depression (49).  
Anxious distress 
In the DSM-IV, severity of depression is assessed using ‘number of criteria 
symptoms’, ‘the severity of the symptoms’ and ‘degree of functional disability’. These 
three specific measures of depressive severity do not correlate well and are not 
equivalent, for example somebody who has more severe symptoms might still have 
a high functional level (50). Hence clinical specifier of severity for major depression 
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has been included in DSM-5. These specifiers are depression with anxious distress, 
with mixed features, with melancholic features, with atypical features, with psychotic 
features, with seasonal features, peri-partum and with complete or partial remission 
“Anxious distress is defined as the presence of at least two of the following 
symptoms during most  of days during a major depressive episode; feeling keyed up 
or tense, feeling unusually restless, having difficulty in concentrating because of 
worry, fear that something awful may happen, feeling that the individual might lose 
control of himself or herself “(16). Previously “mixed anxiety depressive disorder“ 
was considered as a separate entity, however reports of test-retest reliability of 
mixed anxiety depressive disorder found that the diagnosis could not be reliably  
separated from major depression or generalized anxiety disorder (51). So in DSM-5 
“mixed anxiety depressive disorder “was abandoned and anxious distress was 
introduced as specifier to depression to incorporate common anxious symptoms.  
1.3.1 Risk factors of depression  
Risk factors of depression have been categorized into genetic and physical, 
environmental and social risk factors.  
Genetic and physical risk factors 
Genetic risk factors for depression have been reported in twin and family 
studies(52) and studies report it to be of more significance in men than in 
women.(52, 53) Physical risk factors include increasing age (54, 55), being female 
(56, 57), prior depressive episode (58), suffering from physical medical conditions 
(59), ethnicity (60), negative affectivity or neuroticism (61) and history of suicide 
attempts (62) and addictions (63). Genetic and physical risk factors relevant to this 
thesis are discussed in more detail in section 1.3 later.  
Environmental risk factors 
Neighborhood or the surrounding environment (64) inappropriate psychosocial work 
environment (65) , physical trauma(66) are considered as some of the 
environmental risk factors for depression.  
Social risk factors  
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The social risk factors for depression reported in the literature are childhood 
adversity (67, 68), stressful life events (69), poor social support and substance 
abuse (70) and childhood parental loss.(71) Low socioeconomic position is also 
linked to depression (72). 
  
1.3.1.1 Personality trait Neuroticism and depression 
Personality refers to individual differences in characteristic patterns of thinking, 
feeling and behaving (73). This differentiates persons from each other. Costa has 
defined five personality traits, called the “Big Five”, which are broad areas or 
dimensions of personality that can be used to describe human personality (74). The 
domains are called openness, conscientiousness, extraversion, agreeableness and 
neuroticism. Openness to experience is the personality trait which has likes art, 
sentiment, adventure, uncommon ideas, curiosity, and variety of experience. 
Conscientiousness is a personality trait referring to a tendency to show self-
discipline, act with responsibility, and aim for accomplishment; planned behavior 
rather than impulsive; organized, and dependable. Extraversion is the personality 
trait which has energy, positive emotions, urgency, decisiveness, sociability and the 
tendency to seek stimulation in others, and talkativeness. Agreeableness is the 
personality trait that tends to be compassionate and helpful and not doubtful and 
opposed towards others. It is also a measure of ones' trusting and helpful nature, 
and whether a person is generally well tempered or not. Neuroticism is a personality 
trait with the tendency to experience unpleasant emotions easily, like anger, anxiety, 
depression or vulnerability. Neuroticism also refers to the “degree of emotional 
stability and impulse control.” 
Specific traits in personality like neuroticism increases the risk of developing 
depression. In a secondary data analysis on 1000 people, high level  neuroticism 
was a significant prospective predictor of depression (75). In a study conducted on 
270 adolescents, development of personality trait neuroticism with age was 
associated with negatively toned emotional experience and depressive and anxiety 
disorders in young adulthood.(76, 77) Among all five personality traits mentioned 
above, neuroticism is strongly associated with depression (61). 
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1.3.1.2 Genetics and depression    
There are several well established genetic associations to depression in studies of 
animal models and culturally and ethnically homogeneous patient materials (52). 
Studies on Twins  suggest a heritability of 40-50%, and family studies indicate a two- 
to threefold increase in  risk of developing depression among first-degree relatives 
(78). In a large national sample, the heritability of major depression was similar when 
estimated from twin and full/half-sibling designs (79). So far, most genetic studies on 
depression have focused on genes regulating the serotonergic and dopaminergic 
neurotransmission (80). 
Dopamine pathway in genetics and depression 
Deficiency of dopamine in specific areas of the brain, called the mesolimbic 
dopamine system or the brain reward system, contributes to the expression of 
depression (81). Increased   dopamine, produced in synaptic clefts in these areas, 
have been shown to be metabolized by dopamine transporters (DAT) or degraded 
by monoamine oxidase A (MAOA) or Catechol-O-Methyltransferase (COMT) (82). 
COMT metabolizes not only dopamine but also other catechol amines and sex 
steroids, like catechol oestrogens and dietary polyphenols. COMT activity is 
dependent on genetic variations in the COMT gene. COMT contains a functional 
single nucleotide polymorphism (SNP) – rs4680 – that codes for a replacement of 
methionine (Met) for valine (Val) at codon 158. The Met allele has less enzymatic 
activity compared to the Val allele (83). The Val/Val genotype is associated with 
about 40% more effective degradation of dopamine compared to the Met/Met 
genotype (84). This might be a possible link in between depression and the specific 
genotype controlling the dopamine metabolism. 
1.3.1.3 Comorbidity and depression 
Comorbidity is referred  to as the presence of additional diseases in relation to an 
index disease in a person (85). Depression, while being a disabling condition itself, 
when coexists with co-occurring medical condition, makes treatment and recovery 
difficult (86).  Chronic illness increases the risk of depression. Depression is 2 times 
more  common among patients with diabetes mellitus, coronary artery disease, HIV 
infection, and stroke than among patients free of chronic illness (87). Additionally 
depression increases the risk of type 2 diabetes (88) and coronary artery disease 
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(89). Hence the relationship between depression and other acute or chronic medical 
conditions can be bi-directional and it is often difficult to establish clear temporality. 
Non-cardiovascular morbidity is a relatively new term, defined as comorbidities not 
considered as independent risk factors for CVD (90). Non-cardiovascular morbidities 
generally include respiratory, endocrine (excluding diabetes), nutritional, renal, 
hematopoietic, neurological as well as musculoskeletal conditions (91). Coexistence 
of depression and comorbid conditions often leads to overexpression of somatic 
symptoms, like pain, thus complicating the treatment (92). It is also associated with 
reduced quality of life, higher costs, and worse health outcomes and requires 
extensive coordination across various health services (59, 93). 
1.4 CARDIOVASCULAR DISEASES  
CVD are generally stated to as conditions that involve narrowed or blocked 
(thrombosis) blood vessels that can lead to ischemic heart disease (IHD) 
(myocardial infarction, angina) or stroke. This prevents blood from reaching to the 
heart or brain. The most common reason is a pooling of fatty deposits on the inner 
walls of the blood vessels which forms the thrombus (clot) which blocks the arteries. 
Strokes can be caused by blood clots or bleeding from a blood vessel in the brain 
(72). Eighteen million deaths annually is attributed to cardiovascular diseases 
worldwide (94). The incidence of major cardiovascular events has been reported to 
be highest in low-income countries, despite the fact that these countries have lower 
risk-factor burden (95).  
Both myocardial infarctions and strokes contribute to the global burden of CVD. The 
global burden of IHD increased by 29 million disability-adjusted life-years (29% 
increases) from1990-2010 (96). The burden of both ischemic and haemorrhagic 
stroke has increased significantly from 1990-2010 in terms of an increased absolute 
number of people with incident stroke, number of deaths, and number of disability in 
life years lost (97). It is this fatal nature of these specific CVDs (acute myocardial 
infraction, unstable angina and stroke) that they were included as the main outcome 
in all studies of this thesis. 
1.4.1 Acute myocardial infarction and unstable angina  
Acute myocardial infarction is defined as an event of myocardial necrosis caused by 
an unstable ruptured plaque. Clinically it is diagnosed and assessed on the basis of 
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symptoms like chest pain or heaviness, electrocardiogram (ECG), biochemical 
testing, invasive and noninvasive imaging (98). Unstable angina is defined as 
myocardial ischemia at rest or minimal exertion in the absence of death of heart 
muscle (99). Total deaths from ischemic heart disease rose by 19.0%  increasing 
from 7.96 million deaths in 2006 to 9.48 million deaths  in 2016, which mainly 
accounts for the overall increase in total deaths from cardiovascular diseases (7). 
1.4.2 Stroke  
Stroke is manifested as a neurological deficit attributed to an acute focal injury in the 
brain parenchyma due to vascular thrombosis, including cerebral infarction (due to 
arterial thrombosis), intracerebral hemorrhage, and subarachnoid hemorrhage, and 
is a major cause of disability and death globally (100). Stroke is the second most 
common cause of deaths 11.8% of all deaths worldwide (after ischemic heart 
diseases) (101).  
1.4.3 Risk factors for CVD 
Several risk factors for cardiovascular diseases have been reported in the literature. 
Some of them have been classified into genetic, cardio-metabolic, environmental 
/Psychosocial/Physical and lifestyle risk factors.   
Genetic predisposition    
Genetics or family history of CVD are important risk factors for CVD. CVD of early 
onset, have a genetic basis and a host of genes have been identified in connection 
with atherosclerotic CVD (102). Having at least one parent suffering from CVD 
doubles the 8-year risk of CVD among men and by 70% among women (103). 
Cardio-metabolic risk factors  
Cardio-metabolic risk factors include obesity, diabetes, high cholesterol and high 
blood pressure (9, 104). Hypertension is the leading risk factor for CVD (7). Obesity 
is associated with increased risk of CVD and also worsens the CVD risk factors like 
hypertension and high cholesterol.(105) Diabetes is also a major risk factor for CVD 
and almost half of diabetic patients die due to heart disease (106). 
Hypercholesterolemia with an increased serum low-density lipoprotein (LDL) 
cholesterol is a major risk factor for CVD (107).  
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Environmental /Psychosocial/Physical   
Apart from the physical and behavioural risk factors, environmental risk factors, on 
which an individual has little control are also present. These include air pollution 
leading to deaths from ischaemic heart disease and stroke (108), lack of space for 
physical activity (109), dietary regulations on availability of certain high salt food 
(110). Socioeconomic status has strong inverse relation with CVD (111)The 
psychosocial risk factors include the following;, inappropriate psychosocial work 
environment (112), neuroticism (113) and depression (114). The physical risk factors 
include comorbid conditions (115) and physical trauma (116). 
1.4.3.1 Lifestyle  
Physical inactivity, hazardous alcohol use, inadequate nutrition (inadequate fruits 
and vegetable intake) and smoking are the lifestyle behaviors that increase the risk 
of CVD (8, 117). Physical activities of both moderate and vigorous intensity are 
associated with reduced risk of CVD (118). Light-to-moderate alcohol consumption 
has been shown to be linearly associated with a decreased risk of acute myocardial 
infarction.(119) Diet including high-fat and high salt diet, less fruit and vegetable 
intake and smoking are also important risk factor for CVD (95). 
1.4.4 Assessment of CVD 
Assessment of cardiovascular disease can be done based on self-reports(120). 
Clinical diagnostic criteria for ischemic heart diseases include symptoms of chest 
pain, electrocardiogram and troponin I blood test (121). Additionally, specialized 
diagnostic investigations like myocardial perfusion imaging, coronary angiography 
and echocardiography (rest and during exercise) are also used for assessment of 
ischemic heart disease and acute myocardial infraction (122). Clinical diagnostic 
criteria for assessment for stroke is sudden focal loss function of any body part 
(100). Additionally computed tomography and magnetic resonance imaging of the 
brain are specialized diagnostic investigations used for assessment for stroke (123).  
Patient registers from health care facilities are also used for assessment of CVD. In 
this thesis the Swedish National Patient Register (NPR) was used for evaluation of 
CVD. The NPR was founded in 1964 and complete national coverage started in 
1987 (coding adapted from the WHO ICD classification system). Currently, more 
than 99% of all somatic (including surgery) and psychiatric hospital discharges are 
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registered in it (124). It was validated by the National Board of Health and Welfare 
revealed that 85-95% of all diagnoses are valid (125, 126). The validity of diagnosis 
of myocardial infarctions by NPR is 90.3%. It is mandatory for all physicians to report 
data on patients to the NPR (excluding primary care). Each hospital discharge is 
linked to an individual's personal identity number (127).Missing primary (main) 
diagnosis in  NPR is 0.8% for  somatic care, 2.4% for  geriatric care, 3.1% for  
psychiatric care and 0.5% of general surgery which is quite low. (126). The Swedish 
cause of death register has been electronically available from 1952 (128).The cause 
of death register has validity of 77% for cause of death when compared to the cause 
of death expected based on case summaries.(129) 
1.5 DEPRESSION AND CVD 
As mentioned in the previous section, depression is one of the risk factors for CVD. 
The reason that this relation is of importance is that while CVD is linked to mortality, 
depression is linked to disability (1, 7). The existence of depression and later CVD in 
the same individual is therefore associated with worse health outcome. A meta-
analysis including  28 studies on 80,000 patients concluded that  depression was an 
independent risk factor for CVD (10). In the past two decades, some prospective 
studies have found a relatively strong association between depression and 
subsequent events of cardiovascular disease (CVD) in initially CVD free 
populations.(130, 131) In a large retrospective cohort study on 4.6 million Danish 
persons from the general population; adjusted risks of cardiac hospital admissions 
and death were significantly increased to 68%  in persons with hospital admissions 
due to depression.(132). Similarly in another cohort study on elderly community 
dwelling individuals apathy, but not depression, was found to be a strong, 
independent risk factor for incident CVD.(133)  
1.5.1 Depression and Acute myocardial infarction (and unstable angina)  
The INTERHEART study, a large multicentre case–control examination of modifiable 
risk factors for myocardial infarction, found that psychosocial factors (such as locus 
of control, perceived stress, and life events) results in a 2.7-fold increased risk of 
acute myocardial infarction (AMI) (9). A meta-analysis concludes that depression is 
independently associated with increased risk of acute myocardial infarction (134). In 
contrast Rahman et al reported, analysing a cohort study on 36 654 elderly Swedes 
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showed a significant association of untreated depression with ischemic stroke but 
not with coronary heart disease (135).  
1.5.2 Depression and stroke  
Depression has also been associated with stroke (136). A meta-analysis including  
28 prospective cohort studies on  317,540 participants concluded that depression 
increases the  risk of stroke morbidity and mortality (137). A recent longitudinal study 
reported depression as being a risk factor for developing stroke among middle aged 
women (138).  
1.6 POTENTIAL MECHANISMS OF DEPRESSION LEADING TO 
CARDIOVASCULAR DISEASE 
The notion of bio-behavioural model to explain the relationship between depression 
and CVD is gaining support in the literature (139). This model categorises the 
mechanisms into biological and behavioural mediators.(11) (Figure 1. Relationship 
between depression and cardiovascular disorders). 
 
 
 
Figure 1. Relationship between depression and cardiovascular disorders. (Elderon et 
al, 2013) 
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1.6.1 Biological Mechanisms 
Among the Biological dysregulation mechanisms some specific pathways have been 
reported. These include  
(a) Metabolic dysregulation: The dysregulation of metabolic factors including central 
obesity, increased blood sugar, high blood pressure, increased triglycerides and 
decreased HDL cholesterol contributes to the pathophysiology of depression leading 
to CVD. There is consistent evidence associating depression and obesity-related 
components, i.e. central obesity, low HDL cholesterol, hypertriglyceridemia (139, 
140). These factors are also likely to be genetically determined.  
(b) Immuno-inflammatory dysregulation: Depression is associated with dysregulated 
inflammation; an immune response that derives from activation of the innate immune 
system including proinflammatory cytokines( interleukin (IL)-1, IL-6) and tumour 
necrosis factor (TNF)-α) produced within innate immune cells in response to 
immunologic challenge (140). Also increased platelet stimulation and endothelial 
dysfunction in blood vessels is reported  as a potential pathophysiological pathway 
linking depression and CVD (141). 
(c) Autonomic dysregulation: The concept that stress response during natural 
disasters, terror attacks (142)or soccer matches  have been associated with 
increased risk of acute cardiovascular events. Such stressful situations lead to 
activation of cardiac sympathetic nerves (143). There is evidence of hyper 
sympathetic/hypo vagal state among depressed persons. Autonomic dysregulation 
results in sympathetic stimulation leading to tachycardia, blood pressure liability and 
tendencies toward hypertension (144). Studies have also reported that in patients 
with major depression, there is noradrenalin spill over resulting in increased 
sympathetic activity (145). This increased sympathetic activity further leads to 
hypertension which is an established risk factor of CVD (146). 
(d) Hypothalamic-pituitary-adrenal axis activity: Chronic stress is professed by the 
cortex of the brain and conveyed to the hypothalamus, where corticotrophin-
releasing hormone (CRH) resulting in release of cortisol into the blood (11, 147). 
This in turn increases the stress response and blood pressure. 
1.6.2 Behavioural mechanisms 
The behavioural mechanism can be explained by the fact that depressed people 
have more often have unhealthy life style behaviours, i.e. are more likely to smoke, 
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drink hazardous amounts of alcohol, eat an high cholesterol diet and to be less 
physically active (148, 149). Additionally there is a higher likelihood for non-
adherence to medications (e.g. for control of hypertension, diabetes) compared to 
their non-depressed counterparts, thus further worsening of the CVD risk factors and 
leading to CVD(150). Certain specific personality types like neuroticism might be at 
more risk for medication non adherence and this might be a contributory factor (151).  
1.7 KNOWLEDGE GAPS  
There is support for depression linked to an increased risk for CVD. Some risk 
factors are shared between depression and CVD for example genes, socioeconomic 
status, psychosocial work environment, personality trait like neuroticism, comorbid 
conditions. However, whether coexistence of these individual risk factors with 
depression (like high level neuroticism or COMT Val/Met,) increases risk of CVD is 
still a point of debate. Also it would be useful to understand what underlying 
behavioural or biological mechanism exists in the interaction of depression with other 
risk factors leading to CVD. It is important to address these gaps as both depression 
and CVD constitutes a large burden of diseases today, and in order to prevent or 
treat them a clearer understanding of the interacting risk factors and their 
mechanisms is essential. 
1.7.1 Severity of depression and CVD 
Since depression is a risk factor for CVD, it is therefore postulated that the more the 
degree of depression (number of symptoms of depression), the higher the risk of 
CVD might be. The dose-response connection between depression and future risk of 
CVD has not been well studied. In the Nova Scotia Health Survey on 1302 
participants, independent and  an incremental  association between depression and 
incident CHD was detected in a small population-based sample over  a  4-year 
period (152). In the Netherlands Study of Depression and Anxiety involving 2510 
participants, a dose–response association was found for severity of symptoms with 
CVD (153). Holt et al further reported that the association between depression and 
cardiovascular diseases was dependent of the severity of depression at baseline 
(154). However, these studies are based on patients from hospital or clinic settings. 
Hence whether severity level of depression increases risk of CVD in population-
based samples is still not known. Additionally, the role of anxious distress which is a 
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clinical specifier for severity of depression has not been assessed with regard to risk 
of CVD.   
1.7.2 Depression, high level neuroticism and cardiovascular diseases. 
Personality traits , mainly neuroticism may  result in  psychosocial stress  leading  to 
elevated blood pressure, atherosclerosis, and other physiological risk factors (155). 
High level neuroticism (or high negative affectivity) is associated with cardiovascular 
outcomes (156). In the British Health and Lifestyle Survey, higher neuroticism was 
associated with higher risk of coronary heart disease mortality but not with stroke 
mortality (157). The same cohort was followed up again after 5 years and high 
neuroticism was a risk factor for cardiovascular mortality in women with low 
socioeconomic status , whereas in women with higher socio economic status   it was 
protective (158, 159). Pooled analysis from three cohort studies; the Health and 
Retirement Study, the Wisconsin Longitudinal Study graduate and the Sibling 
samples (n=24,543) have been included in a study by Jokela et al (113). This study 
concluded that high level neuroticism was a risk factor for coronary heart disease 
mortality but not for stroke mortality. Hence whether high level of neuroticism 
increases risk of CVD in depressed patients is still under debate. 
1.7.3 Depression, High COMT Val158Met, and CVD 
COMT Val158Met is of interest in the relation between depression and CVD, as it 
focuses mainly on the catecholamine and dopamine, which are also the essential 
molecules involved in the pathogenesis of cardiovascular diseases. Previous studies 
revealed that there is an association between COMT Val158Met and depression in 
men and also that COMT Val158Met interact with environmental factors on the risk of 
depression (160). Studies are lacking on the association between COMT Val158Met 
and cardio-metabolic factors. In one study low activity COMT genotype was shown 
to be protective for myocardial infarction (161). Another study reported that a low 
activity COMT genotype Val158Met, was associated with CVD and  abdominal 
obesity in men (162). Hence, whether high COMT activity genotype Val158Met in 
depressed patients contributes further to an increased risk of developing 
cardiovascular disorders is still not known. 
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1.7.4 Depression, non-cardiovascular morbidity and CVD  
The interacting pathophysiology of diseases within an individual, complicating 
diagnosis and treatment of people with multiple comorbid conditions is challenging 
(163). Also care of such patients become difficult by the physicians and family (164). 
So far most clinical practice guidelines focus on care of specific disorders. Recent 
literature suggests that multiple comorbid conditions is not only a problem of elderly 
patients, but has also become prevalent in non-geriatric populations (165). Number 
of comorbid conditions and more importantly non-cardiovascular morbidity, have 
been reported to increase risk of CVD (specifically heart failure) and has been 
considered an important marker of prognosis in patients with heart failure.(166, 167) 
Non-cardiovascular morbidity have also been linked to increased risk of heart 
diseases(168). The effect of coexistence of depression and non-cardiovascular 
morbidity on the risk of CVD, has to our knowledge been paid less attention. We 
could find one study by Atlantis et al concluding that the association between 
depression and CVD mortality is partially mediated by comorbid conditions, as well 
as unhealthy lifestyle behaviors (169). 
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2 MAIN AIM AND RESEARCH QUESTIONS 
The main aim of the PhD thesis is to increase the knowledge on the association 
between depression and cardiovascular diseases. This will be achieved by 
answering the following research questions: 
1. Is there effect of severity of depression and anxious distress on the association 
between depression and cardiovascular diseases? 
2.  Is there effect of neuroticism on the association between depression and 
cardiovascular diseases? 
3. Is there effect of COMT Val158Met polymorphism on the association between 
depression and cardiovascular diseases? 
4. Is there effect of non-cardiovascular morbidity on the association between 
depression and cardiovascular diseases? 
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3 MATERIALS AND METHODS 
3.1 STUDY DESIGN AND SETTING  
Data for this thesis was derived from a longitudinal cohort study- the PART study - 
(In Swedish short for: Psykisk hälsa, Arbete och RelaTioner). The PART study is a 
large longitudinal population based study on risk and protective factors for mental 
health, among adult people residing in the Stockholm County, Sweden.(170) It 
includes three waves: wave 1 (W1) with data collection in 1998-2000, wave 2 (W2) 
in 2001-2003 and wave 3 (W3) in 2010. For this thesis, W1 and W2 were used for 
assessment of depression. Participants were followed for CVD outcomes in W3 
(Study I), National Patient register (2001-2014) and the cause of death register 
(2001-2014). (124), (128) In Study I, CVD was assessed using W3 data in addition 
to the National Patient register (2008-2011) as data, at time of analyses, from the 
register was available only during 2008-2011(Figure II.Schematic overview of the  
subjects from the PART study included in the sub-studies in the thesis.) 
3.1.1 Study Participants  
Inclusion criteria  
1) Being a Swedish citizen residing in Stockholm County. Only Swedish citizens 
were chosen to alleviate the possibility of linguistic difficulties.  
2) Adults aged > 20 years of age were chosen since the PART study focused 
primarily on those who belonged to the wage-earning age range.  
Exclusion criteria  
Those who were living in remote municipalities with more than one hour travelling 
time to the research center.  
3.1.2 Waves of the PART study  
Wave 1: In 1998-2000, the population of Stockholm County full filling the sampling 
criteria were 858000.The PART study sample, included 19,744 adult individuals > 20 
years of age registered in the Stockholm County and randomly selected from the 
Population register of the Stockholm County. Only 19,457 could be reached due to 
address issues. Among the latter, 10,443 individuals responded to the questionnaire 
at wave 1 (53% of the intended sample). Non-response analyses were done by 
using available administrative and health registers. Of those who responded, data 
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was analyzed for 10341 participants. Male gender, less than 50 years of age, low 
income, low educational level, living alone and country of birth outside the Nordic 
countries were strong elements of non-participation (171). However, associations for 
all hospital discharge psychiatric diagnoses were similar among participants and 
non-participants when related to gender, age, income, residential status, education 
and country of origin. 
Wave 2: All participants who participated in wave 1 received a second, almost 
identical questionnaire three years later. The participation rate at this follow-up 
phase was 83% (n= 8,622). Reasons for non-response was like those in W1 (172). 
Wave 3: All participants who participated in wave 2 received a third, almost identical 
questionnaire seven to eight years after they had answered the second one. The 
participation rate at the third follow-up phase was 61% (n= 5,228).  
DNA collection wave (2006-2007 and 2010-2011): All participants from W1 
(n=10443) were invited to participate in the DNA collection wave to contribute their 
saliva for DNA analysis. In total 4349 (41%) participated. The reasons for non-
participation have been reported to be mainly due to lack of personal relevance of 
DNA contribution and uneasiness related to DNA usage (173).  
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Figure II.Schematic overview of the subjects from the PART study included in 
the sub-studies in the thesis.  
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3.2 ETHICAL CONSIDERATIONS 
The standard principles of ethics according to the Helsinki declaration were 
considered and applied to the studies of this thesis. All participants received a 
detailed pamphlet with instructions about the PART study. Informed consent was 
taken keeping in mind the principle of autonomy for all participants and it was stated 
that the participation was voluntary and could be ended anytime. Confidentiality was 
maintained among participants, so that none of the participants were aware about 
any information of the other participant. This is necessary as each participant has a 
right of privacy for his/her personal or health related information. The ethical problem 
that was encountered was that some participants were not aware of the fact that 
they were depressed. All persons who revealed that they had suicidal thoughts more 
than half of the time during the last two weeks was called by the research staff.  If 
needed they were informed about available care, some were offered a visit and talk 
to one of the psychiatrists in the research team. Research staff was also available by 
phone and email throughout the study if the participants wanted.  At the end of the 
questionnaire there was free space for comments from the participants. These were 
all read and in case something alarming was written the participant was contacted, 
e.g. one participant wrote about sexual abuse another about physical abuse. In order 
to decrease the rate of internal missing data all participants who did not answer all 
the questions were contacted. Following the principle of beneficence to the 
participants, they were then offered to be referred to a psychiatrist.  
The studies were approved by the Ethical review board at Karolinska Institutet, 
Stockholm (96-260, 01-218, 03-302, 2009/880-31, 2012/808-32, 96-260, 97-313, 01-
218, 03-302, 2004-528/3, 2009/880-31, and 2012/808-32). 
3.3 EXPOSURES  
3.3.1 Depression  
Major depression inventory (MDI) 
Major depression inventory (MDI) was used for assessment of depression. It is a 
self-rating scale, shown to have high validity both in clinical and non-clinical 
samples.(174, 175). (See Appendix A for MDI scoring key and instructions). Validity 
studies of the MDI have been done in Swedish population (176), in clinical 
settings in different European countries.(41, 49, 177) The sensitivity of MDI was 
0.78 and the specificity was 0.78 in a study based on wave 1 of PART.(176) MDI 
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has shown the highest coefficient of homogeneity when compared to BDI and HAM-
D –Hamilton Depression Rating Scale (178).  
Depressive symptoms during the past 2 weeks were assessed with a slightly 
modified version of the MDI for the PART study. To make the PART scale in 
accordance with criteria of a major depressive episode in DSM-IV, some symptom 
questions were modified or added, i.e. the question “Have you felt either very 
restless or rather subdued” was divided into two separate questions: “Have you had 
trouble sleeping at night” and ”Have you suffered from reduced appetite” were 
supplemented by the questions ”Have you needed to sleep more than usual” and 
”Have you had increased appetite or increased in weight recently”. When analyzing 
the data the questions on sleep and appetite was considered in combination. One 
question was added: “Have you felt as if you wanted to take your life”. Moreover, 
also questions on severity of social impairment due to the symptoms and duration of 
the symptoms were added. The full PART instrument was used to screen for any 
symptoms of depression while one of the questions was also used to screen 
specifically for suicidal thoughts. The MDI includes 10 item questions (question 8 
and 10 have 2 sub questions a and b). For items 8 and 10, response alternative a or 
b with the highest score is considered. Each item has 5 response categories; all the 
time (5), most of the time (4), slightly more than half of the time (3), slightly less than 
half of the time (2), some of the time or at no time (1). For simplification the items 
were dichotomized to indicate the presence (=1) or absence (=0) of each of the 
symptoms. The first three items of MDI are considered present for answer categories 
from 4 to 5 (i.e., most of the time, all the time). For the remaining items (items 4–10, 
response categories from 3–5 (i.e., more than half of the time, most of the time and 
all the time) are included when scoring the symptoms as being present. The MDI is 
used both as a diagnostic instrument with the algorithms leading to the DSM-IV or 
ICD-10 categories ‘major ‘or ‘moderate to severe’ depression, and as a measuring 
instrument in which the total score is a sufficient statistic (49). Assessment of 
depression was based on responses in both W1 and W2, and the wave with highest 
score was used to determine depression and severity of depression.  
3.3.2 Severity of Depression  
Based on total score of MDI severity of depression was assessed. The 10 items of 
MDI are added up, to a mathematical  score ranging from 0-50 (49).  Mild depression 
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was defined as a total score of 20-24, moderate depression; 25-29 and severe 
depression >30. Those scoring < 20 were considered as non-depressed.  
3.3.3 Anxious distress  
Concomitant anxious distress was used as a specifier of severity of depression 
according to DSM-5(17).Anxious distress is considered as a specifier of depression 
severity according to DSM –V and was defined according to the presence of at least 
two of the following symptoms;” During the previous two weeks: feeling keyed up or 
tense, feeling unusually restless, difficulty in concentrating because of worry, fear 
that something awful might happen and fear of losing self-control.” Each symptom 
was assessed using a 5- or 6-point Likert scale, and, for simplicity, the response 
alternatives were merged as yes or no, and rated according to DSM-5 number of 
symptoms (no anxious distress = none or one symptom; mild anxious distress = two 
symptoms; moderate anxious distress = three symptoms; and moderate to severe 
anxious distress = four to five symptoms) (179). (See appendix B for DSM-5 criteria 
for anxious distress and corresponding questions used from scales in mental health 
in the PART study to assess anxious distress.) 
3.3.4 Neuroticism 
The Swedish universities Scales of Personality (SSP) was used to assess 
neuroticism (paper II) (See appendix C for the Swedish scale of personality reflecting 
neuroticism, mean and T score) (180). SSP is an advanced and composite version 
of the neo personality inventory which originally comprised of 240 questions to 
assess the Big five aspects of personality (74) and the Karolinska Scales of 
Personality (KSP) inventory comprised of 135 items.(181) SSP is a revised, 
condensed, advanced and psychometrically evaluated version of the Karolinska 
Scales of Personality (KSP).(180). The SSP inventory consists of 91 items grouped 
into 13 different scales (See Table 1 for a list of scales in SSP). 
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Table 1. List of the 13 SSP scales  
Scale label 
Somatic Trait Anxiety 
Psychic Trait Anxiety 
Stress Susceptibility 
Lack of Assertiveness 
Impulsiveness 
Adventure Seeking 
Detachment 
Social Desirability 
Embitterment 
Trait Irritability 
Mistrust 
Verbal Trait Aggression 
Physical Trait Aggression 
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Scoring of SSP 
Each of the 91 items is given as a statement with a four-point response format, 
ranging from 1 to 4, 1 point for the” disagree” and so on to 4 points for the “agree”. It 
has been demonstrated that a four-point response format gives better psychometric 
properties than a dichotomous format. The reported Cronbach’s alpha coefficient for 
internal consistency of SSP ranges from 0.59 to 0.84, and the mean inter-item 
correlations ranges from 0.17 to 0.43. Based on this the responses personality 
facets were grouped into  3 main traits was done.(180) Three derived factors which 
also correlate with the personality theories are (1) neuroticism (2) aggressiveness 
and (3) extraversion factor. In this study factor 1 indicating neuroticism was used. 
Factor 1 is mainly comprised of 3 scales assessing broad and narrow traits of 
neuroticism including: 
 Somatic trait Anxiety 
 Stress Susceptibility 
 Embitterment. 
High versus low level Neuroticism  
Scores for neuroticism was divided into tertile; cut-off levels at 33.3 and 66.6; lowest 
tertile ≤ 33.4, middle tertile ranging between 33.5to 66.6 and highest tertile >66.6. 
Scores at 66.6 tertile and below were considered as low levels of neuroticism and > 
66.6 tertile as high level neuroticism. This cut-off was used to capture those scoring 
higher in a separate category. Low-level neuroticism was used as reference group in 
the analysis. 
3.3.5 COMT Val158Met  
DNA was collected using a self-administered whole-saliva DNA sample collection kit 
(Oragene, DNA Genotek Inc., Ottawa, Canada) sent to the participants’ homes. 
Saliva was obtained from participants and genomic DNA was extracted using 
Oragene Purifier. The COMT Val158Met (rs4680) genotype was successfully 
obtained for 3731 persons (91%) using TaqMan SNP genotyping assays applying an 
ABI 7900 HT instrument (Applied Bio systems, Foster City, CA).(182) Val/Val (G/G) 
was considered as the, at risk allele in accordance with previous studies (161, 183) 
and Met/Met (A/A) or Met/Val (A/G) was used as reference.  
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3.3.6 Non-cardiovascular morbidity  
Non-cardiovascular conditions were based on self-reports to the following questions 
(a) Are you currently treated for a disease (e.g. peptic ulcer disease) (85). The same 
question was asked for each of the following diseases; current occurrence of 
neurological disorders, endocrinological disorders, respiratory disorders, 
gastrointestinal disorders (dyspepsia or bowel or liver), kidney and urinary tract 
disorders, genital disorders, serious infections, tumors (benign or malignant), 
rheumatologic disorders, other heart diseases(other than ischemic heart disease) 
skin disorders and psychiatric disorders (other than depression).Those who 
answered yes to any of the above diseases were considered to have non-
cardiovascular morbidity. 
3.4 OUTCOME  
Acute myocardial infarction, unstable angina (including hypertensive heart disease) 
and stroke were used for assessing the CVD outcomes for all four studies and the 
outcome was then linked to the PART data from W1 and W2. Also, for the specific 
studies in this thesis, those who reported current or a history of myocardial infarction 
or stroke in wave 1 were excluded to ensure a CVD free population at time of follow 
3.4.1 Study 1 
For study I, CVD outcomes were based on NPR or self-reports. At time of analyzing 
paper I, register data was available for 2008-2011. Self-reports on CVD was used as 
reported in the health status questions in W3.” Are you currently or have you 
previously been on treatment for angina pectoris or have you received this diagnosis 
from a physician? “Corresponding questions were asked for myocardial infarction, 
high blood pressure and stroke. The following hospital discharge diagnoses (main 
and secondary) were derived from the NPR and coded according to ICD10: 
ischemic/hypertensive heart disease; hypertensive diseases (ICD-10: I11-13), 
ischemic heart diseases (I20-25), heart failure (I50), other peripheral vascular 
diseases, embolism and thrombosis (I73-74) and stroke (I60-67 and I69). 
3.4.2 Study II, III and IV 
 Participants were followed in the NPR for CVD outcomes from 2001-2014. The 
endpoints considered were: time of CVD outcome, death, or end of follow up (i.e. 
2014). Time to event was calculated in years = time of CVD event (admission date) 
minus start of follow-up for those who had and CVD event, and end of follow-up 
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minus start of follow-up for those who did not have CVD event. The hospital 
discharge diagnoses (main and secondary) derived from the NPR were same as 
used for study I. 
3.5 COVARIATES  
The following variables were selected as covariates: age, gender, socioeconomic 
position (SEP), hypertension, and diabetes, all assessed at baseline (W1). The 
reason to consider these as confounders was that they have been previously 
associated with depression and CVD independently and do not come in the causal 
pathway (when considered at baseline) between depression and CVD (133, 184, 
185). History of ischemic heart disease and stroke were measured at W1 and were 
considered as previous history of CVD and persons reporting this were excluded 
from analysis as mentioned earlier. We considered smoking, hazardous alcohol use, 
BMI and physical inactivity as potential mediators since they are established risk 
factors for both depression and CVD but are also likely to come in the causal 
pathway (9, 186-190). For study III only age and BMI were considered as covariates. 
Covariates were recorded from W1 in general, for smoking and physical activity, 
data was only available in W2.  
Gender and Age at W1: Age was categorized into 20-30 years, 31-40 years, 41-52 
years and >52 years. Age 20-30 years was considered as reference. 
Socioeconomic position (SEP) in W1 was measured through occupational groups 
defined according to the Nordic Standard Occupational Classification (NSOC) of 
1989 (191). SEP was classified into five groups: high/intermediate level salaried 
employees; assistant non-manual employees; skilled workers; unskilled workers; 
and self-employed (including farmers). High/intermediate level salaried employees 
was the reference as this group is relatively less disadvantaged than the other 
groups.  
Physical inactivity was defined as not exercising regularly (i.e. at least three times a 
week). 
Smoking habits reported in W2 was classified as regular smoker, occasional smoker, 
previous smoker and never smoker (192). Never smoker was used as reference 
category as they are expected to have the lowest risk of CVD. 
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Hazardous alcohol use in W1 and W2 was assessed by the Alcohol Use Disorders 
Identification Test (AUDIT) tool (193) and dichotomized according to the Swedish 
cut-off points (≥8 points for men and ≥6 points for women) (194).  
Treatment for psychiatric disorders was assessed using questions inquiring whether 
the participant had sought psychiatric consultation in either W1 or W2.   
Diabetes mellitus and hypertension at W1 were assessed by asking the participants 
if they suffered, at present or in the past, from diabetes or hypertension. 
Body mass index (BMI) was calculated from height and weight (i.e. weight in kg 
divided by height in m2). 
For variables for which data was available from both W1 and W2, a combined 
variable was created for both waves indicating presence in both waves or maximum 
value in either wave for a continuous variable (e.g. body mass index). 
3.6 STATISTICAL METHODS  
3.6.1 Descriptive statistics  
Mean and standard deviation were used for quantitative variables, and frequency 
and percentage for categorical variables for all four papers. Also, for the specific 
studies in this thesis, those who had history of myocardial infarction or stroke 
(baseline CVD); 2.6 %( n=267) were excluded, so there is a CVD free population to 
follow. This information was collected based on self-report at baseline.  
3.6.2 Missing data  
All participants with partially missing responses were approached through telephone 
calls to fill this data. Imputation of missing values for MDI was accomplished when 
there were missing answers for one or two of the ten questions. If answers were 
missing for more than two questions, the response was left as missing. The missing 
answers were imputed with the mean value of the questions in the answered items. 
The number of missing answers for three or more questions was low, 0.2% (n=23) in 
W1 and 1.4% (n=121) in W2. The maximum number of missing values for questions 
on personality trait neuroticism (paper II) were as follows; somatic trait anxiety 0.3% 
(n=29), stress susceptibility 0.3% (n=29) and for embitterment 0.4 % (n=29). As 
there was no partially missing data on the SSP, no imputation was done for the three 
subscales i.e. somatic trait anxiety, stress susceptibility and embitterment. SEP had 
missing data of 24%, due to administrative reasons. Additional information on 
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occupation was derived from reported main daily activity and included in the above 
categories if the participants reported to be retired, students or self-employed. This 
reduced the missing in SEP to 5 %. Missing in smoking was 17 % consisting of 1719 
(16%) who did not participate in in W2 and 146 (1.4%) did not respond to questions 
related to smoking. Missing in physical inactivity was 17 % consisting of 1719 (16%) 
who did not participate in W2, and 112 (1.0%) did not respond to questions related to 
physical inactivity. 
3.6.3 Logistic and Cox regression analysis for paper I 
For paper I logistic regression was used as participants were followed for CVD 
outcome through self-reports in W3 and in 2008 to 2011 through NPR. The reason to 
include both self-reports and register data was to reduce the chance of self-reporting 
bias. However, after additional register linkage we received corresponding register 
data for 2001-2014.Cox regression was employed to estimate hazard ratios (HR) 
and corresponding 95% confidence intervals (95% CI) were calculated. To assess 
severity of depression, those depressed were categorized into mild, moderate and 
severe. For the sub-analyses including depression and anxious distress; we used 
those with neither depression nor anxious distress as reference. Separate models 
were constructed to adjust for confounders and potential mediators. Subgroup 
analysis for IHD and stroke were also done. Model 1 was adjusted for socio 
demographic factors including age, gender and SEP, and model 2 was additionally 
adjusted for diabetes, hypertension, and lifestyle factors (i.e., smoking, physical 
inactivity, hazardous alcohol use and BMI) 
3.6.4 Cox regression analysis for paper II  
Cox regression models were constructed to determine hazard ratios with 95 % 
confidence intervals using survival analysis. Adjustments in models were the same 
as for paper 1. 
Interaction analysis  
Additive interaction was estimated measuring interaction on an additive scale as it is 
more appropriate for assessing the public health importance (195) and based on 
dummy variables of depression and levels of neuroticism. Four dummy variables 
were created; low level neuroticism with no depression (reference), low level 
neuroticism with depression, high level neuroticism with no depression, and high-
level neuroticism with depression. Synergy index (S) was calculated to confirm if 
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additive interaction was present. S = 1 means no interaction or exactly additively; 
S>1means positive interaction or more than additivity; S<1means negative 
interaction or less than additivity. S can range from 0 to infinity.(196)  
Further, multiplicative interaction was estimated using main effect model with and 
without multiplicative interaction between depression and neuroticism and p-value 
was calculated using the Log likelihood test. Multiplicative interaction is often 
checked to see the magnitude of the interaction effect. 
3.6.5 Logistic regression for paper III 
Comparative analysis between depressed and non-depressed participants was done 
where appropriate using Student t-test and chi square test. We could not do cox 
regression for paper III due to smaller sample size. Logistic regression was used to 
calculate odds ratios (OR) and corresponding 95% confidence intervals (95 %CI) for 
depression and CVD according to COMT Val158Met, adjusting for age and body 
mass index (BMI). We did not adjust for additional covariates as we thought that it 
will not have effect on the genetic makeup .To determine the combined effect of  
COMT Val158Met  and depression on future risk for CVD, logistic regression analyses 
were performed using the four dummy variables; Met carriers (A/A plus A/G) with no 
depression (reference), Met carriers (A/A plus A/G) with depression, Val/Val (G/G) 
with no depression, and Val/Val (G/G) with depression. Additive and multiplicative 
interaction was estimated in the same way as for paper II 
3.6.6 Cox regression analysis for paper IV 
Cox regression models were constructed to determine hazard ratios with 95 % 
confidence intervals using survival analysis. Exposure was depression and non-
cardiovascular morbidity. Four dummy variables were created; no non-
cardiovascular comorbidity with no depression (reference category), non-
cardiovascular comorbidity with depression, non-cardiovascular comorbidity with no 
depression, and non-cardiovascular comorbidity with depression. Adjustments in 
models were done as for paper II Additive interaction was calculated with synergy 
index as for paper II 
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4 RESULTS  
4.1 SEVERITY LEVEL OF DEPRESSION (AND ANXIOUS DISTRESS) AND 
CVD (PAPER I) 
For descriptive statistics of all variables, see table 3. Distribution of covariates 
among PART participants overall and stratified by depression status. The prevalence 
of depression, according to MDI was 14.4% (n=1488); 5.2% (n=534) had mild, 3.5% 
(n=367) moderate and 5.6% (n=587) had severe depression. Applying the DSM-IV 
algorithm, the overall prevalence of depression was 7.6% (n=790). Anxious distress 
was present in 23 % (n=2522) of the participants. At follow-up 6.5% (n=676) had 
CVD (Table 4). 
Table 3. Distribution of covariates among PART participants overall and 
stratified by depression status.  
 Overall  Depressed1 Not depressed  P-value2 
 N=10341 n=1488 n=8832  
 N (%) n (%) n (%)  
Mean age (SD) in years 41.3 (12.4) 39.56 (11.9) 41.67 (12.5) <0.001 
Age group (in years)     
19-30 2595 (25.1) 432(29.0) 2160(24.5) <0.001 
31-40 2476 (23.9) 364(24.5) 2102(23.8)  
41-52 2733(26.4) 421(28.3) 2308(26.1)  
>52 2534(24.5) 271(18.2) 2259(25.6)  
Male gender 4620 (44.0) 463 (31.1) 4146 (46.9) <0.001 
Socio-economic position    0.38 
High and intermediate level salary 4702 (45.5) 493 (37) 4206 (50.2)  
Assistant –non-manual workers 1438 (13.9) 222 (16.7) 1215 (14.5)  
Skilled workers 665 (6.4) 94 (7.1) 570 (6.8)  
Unskilled and semiskilled workers 1204 (11.6) 233 (17.5) 968 (11.6)  
Self-employed (other than professional) 729 (7.0) 80 (6.0) 649 (7.7)  
Retired 435(4.2) 122(9.2 311(3.7)  
Students 552(5.3) 88(6.6) 459(5.5)  
IHD 193 (1.9) 47 (3.2) 143 (1.6) <0.001 
Stroke 86 (0.8) 23 (1.5) 63 (0.7) 0.003 
Hypertension 716 (6.9) 126 (8.5) 590 (6.7) 0.01 
Diabetes mellitus 221 (2.1) 38 (2.6) 181 (2.0) 0.20 
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Table 3 continued     
Smoking     <0.001 
Regular 1289 (12.4) 306 (24.5) 983 (13.6)  
Occasional smoker 889 (8.6) 148 (11.9) 741 (10.3)  
Ex-smoker 2502 (24.1) 331 (26.5) 2171 (30.0)  
Never smoker 3796 (36.6) 462 (37.0) 3333 (46.1)  
Physical inactivity 3936 (46.3) 697(55.9) 3237(44.6) <0.001 
Mean BMI (SD) in kg/m2 24.97 (3.9) 25.13 (4.4) 24.93 (3.7) 0.1 
Hazardous alcohol use 2605 (25.2) 544 (36.6) 2060 (23.3) <0.001 
Sought treatment for psychiatric disorders 2365 (22.8) 821 (55.2) 1542 (17.5) <0.001 
Severity of depression (MDI)1     
Mild  534 (5.1)   
Moderate  367 (3.5)   
Severe  587 (5.6)   
Anxious distress symptoms    <0.001 
Mild 1729 (16.7) 539 (36.3) 1189 (13.5)  
Moderate/severe 793 (7.7) 628 (42.3) 165 (1.9)  
Personality trait neuroticism     
Lowest 2828(27.34) 40(3.2) 2788(38.5)  
Middle 2798(27.05) 198(15.9) 2600(35.9)  
highest 2866(27.7) 1004(80.8) 1862(25.7) <0.001 
Non cardiovascular morbidity  1356 (13.1) 323(21.7) 1026 (11.6) <0.001 
1 Depression assessed by Major Depression Inventory, 2Pearson chi square test and independent sample t test 
were used as appropriate 
 
Table 4. Distribution of CVD in PART participants overall, and stratified by 
depression status (paper I, II and IV). 
 Overall  Depressed1 Not depressed  P-value1 
 N=10341 n=1488 n=8832  
 n (%) n (%) n (%)  
Cardiovascular diseases  676 (6.5) 109 (7.3) 564 (6.4) 0.09 
Ischemic/hypertensive heart 2 435 (4.2) 71(4.8) 361(4.1) 0.12 
Stroke 3 298 (2.9) 53 (3.6) 245 (2.8) 0.05 
1 Chi square test was used to determine p values, 2 (ICD10 codes: I11–13, I20–25, 10: I50), I73–74), 3 (ICD10: I60–67 and I69) 
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Depression was associated with risk of future CVD (OR 95% CI 1.9 (1.4, 2.5). The 
association weakened after adjusting for confounding factors (age, gender) into 
account OR 95% CI 1.7 (1.2, 2.3), but remained increased in the final model after 
adjusting for SEP, diabetes, hypertension and lifestyle factors (OR 95% CI 1.5 (1.1, 
2.1). Detailed results on severity level of depression and CVD are reported in the 
paper. Repeating the analyses using Cox regression (not presented in paper I) 
showed that depression was associated with increased risk for CVD (HR 95% CI 1.5 
(1.1, 2.0), the risk remained after adjustment for confounders and mediators in the 
final model (HR 95% CI 1.3 (1.0, 2.0). Regarding severity of depression, overall 
increased hazard ratios of 1.3 to 2.0 were seen for the different severity levels of 
depression, with the highest HR for moderate depression (HR 95 % CI 2.0 (1.3, 3.2). 
Additionally, those who were depressed with concomitant anxious distress were at 
higher risk for CVD; HR 95% CI 2.0 (1.2, 2.3) (Figure III. Adjusted Hazard ratio for 
CVD according to severity level of depression, Table 5.) 
 
 
1Adjusted for age, gender SEP 
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Figure III. Adjusted hazard ratio1 for  CVD according to 
severity level of depression
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4.2 DEPRESSION, HIGH LEVEL NEUROTICISM, AND CVD (PAPER II) 
Mean (SD) t-score for neuroticism was 145 (SD 24.0); somatic trait anxiety 47.9 (SD 
9.7), stress susceptibility 51.1 (SD 8.1) and for embitterment 46.5 (SD 9.9) 
respectively. High level of neuroticism was present in 27.7% (n=2866) of the 
participants and of these persons 65.0% (n=1862) were not depressed and 35.0% 
(n=1004) were depressed. Table 3. At follow-up 6.5% (n=676) had CVD. 
Having high level of neuroticism was associated with increased risk of CVD; HR=1.5 
(95% CI 1.2, 2.0). Those who were depressed and had high level of neuroticism had 
a further increased risk for CVD (HR 95% CI 2.0 (1.3, 2.6)) versus those who were 
depressed and had low level of neuroticism (HR 95% CI 1.0 (0.4, 2.1)) (Figure IV. 
Adjusted Hazard ratio for CVD according to depression status and level of 
neuroticism, Table 5. Depression severity, neuroticism, Non-cardiovascular morbidity 
and risk of CVD in depressed participants) Additive interaction, revealed a synergy 
index of 1.7(95% CI 0.4, 6.3). However, no evidence for multiplicative interaction 
between depression and neuroticism for risk of CVD was seen (p-value for log 
likelihood ratio= 0.4). 
 
1Adjusted for age, gender SEP 
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Table 5. Depression severity, neuroticism, non-cardiovascular morbidity and 
risk of CVD1 in depressed participants  
 CVD  
n=537 
 Model 12 Model 23 
 HR 95 % CI  HR 95 % CI 
Depression   
No  Ref  Ref 
Yes  1.5 (1.1,2.0) 1.3 (1.0,2.0) 
Level of depression (MDI)   
No depression Ref  Ref  
Mild depression 1.3 (1.0,2.0) 1.2 (1.0,2.0) 
Moderate depression 2.0 (1.3,3.2) 2.0 (1.2,3.1) 
Severe depression 1.3 (1.0,2.0) 1.1 (1.0,2.0) 
Depression (MDI) with/without 
symptoms of anxious distress 
  
No depression or anxious distress Ref  Ref  
Anxious distress 1.03 (1.0,1.4) 1.0 (1.0,1.4) 
Depression alone  1.3 (1.0,2.5) 1.3 (1.0,2.4) 
Depression with anxious distress 2.0 (1.1,2.3) 1.4 (1.0,2.0) 
Depression and Neuroticism    
No depression & low neuroticism Ref  Ref  
Depression & low neuroticism 1.0 (0.4,2.1) 1.0 (0.4, 2.3) 
No depression & high neuroticism 1.4 (1.1,2.0) 1.4 (1.1,2.0) 
Depression & high neuroticism 2.0 (1.3,2.6) 2.0 (1.2,2.4) 
Depression and non-cardiovascular 
morbidity  
  
No depression & No Non-
cardiovascular morbidity 
Ref  Ref  
Depression & No Non-cardiovascular 
morbidity 
1.4 (1.0,2.0) 1.3 (1.0,2.0) 
No depression & Non-cardiovascular 
morbidity 
1.5 (1.1,2.0) 1.4 (1.0,2.0) 
Depression & Non-cardiovascular 
morbidity 
2.1 (1.4,3.4) 2.0 (1.1,3.3) 
1 Baseline CVD excluded, 2 Adjusted for age, gender, SEP, 3 Adjusted for age, gender, SEP, baseline 
DM, baseline hypertension, physical inactivity, BMI, smoking and hazardous alcohol consumption. 
 
4.3 DEPRESSION, HIGH ACTIVITY COMT VAL 158MET, AND CVD (PAPER III) 
Out of the 3525 participants with COMT Val158Met data 1094 (31.0%) had Met/Met 
genotype, 1720 (48.0%) were Met/Val and 711 (20.2%) were Val/Val. The genotype 
distribution was in Hardy Weinberg equilibrium (p=0.31). Those homozygous for 
Val/Val showed a borderline reduced risk for depression (OR 95% CI 0.70 (0.60, 
1.0). Similar risk estimates were seen after stratification for gender. However, those 
who had Val/Val had an increased risk for future CVD (OR95% CI 1.3 (1.0, 1.7)). 
Stratification for gender showed that the OR point estimate for risk for later CVD was 
higher among women than men (OR 95% CI 1.5 (1.0, 2.4) versus (OR 95% CI 1.1 
(1.0, 1.7)). 
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Those with depression and the high COMT enzyme activity genotype (Val/Val) had a 
three times higher risk of later CVD (OR 95% CI 3.6 (2.0, 6.6)) compared to those 
non-depressed carrying the Val/Val allele. This effect on risk for CVD was higher in 
women compared to men (OR 7.0 (95% CI, 3.0, and 14.0) versus OR (95% CI 2.1, 
(1.0, 6.8)). (Figure VI. Adjusted *Odds ratio for CVD according to depression status 
and COMT Val 158 Met, Table 6.) 
 
1Adjusted for age and BMI 
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Figure IV. Adjusted odds ratio1 for CVD according to depression 
status and COMT Val 158  Met 
Lower CI OR upper CI
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Table 6. Interaction between COMT Val158Met and depression for future risk of 
CVD, stratified by gender.  
 All  
n=3525 
Men  
n=1495 
Women  
n=2030 
 Met/Met or 
Met/Val 
Val/Val Met/Met or 
Met/Val 
Val/Val Met/Met or 
Met/Val 
Val/Val** 
 n=2814 n=711 n=1179 n=316 n=1635 n=395 
Depression n CVD/n Non-CVD 
No 146 /2205 42/576 102/947 31/258 44/1258 11/318 
Yes 33/430 15/78 15/115 4/23 18/315 11/55 
 Odds ratio (95% confidence interval)1 
Depression        
No 1 (Ref) 1.1(0.8,1.6) 1 (Ref) 1.1(0.73,1.7) 1 (Ref) 1.0(0.50,2.0) 
P values - 0.5 - 0.5 - 0.10 
Yes 1.5(1.0,2.3) 3.6(2.0,6.6) 1.8(1.0,3.4) 2.1(1.0,6.8) 2.0(1.1,3.5) 7.0(3.0,14.0) 
P values  0.03 <0.001 0.05 0.20 0.01 <0.001 
1 Odds ratio (OR) for Val/Val (G/G) with no depression, Val/Val (G/G) with depression and Met carriers (A/A plus 
A/G) with depression, adjusted for age and body mass index. Met carriers (A/A plus A/G) with no depression was 
the reference group.  
4.3.1 DEPRESSION, NON-CARDIOVASCULAR COMORBIDITY AND CVD 
(PAPER IV) 
Non-cardiovascular morbidity was present in 13.1% (n=1356) of the participants. 
(Table 3. Distribution of covariates among PART participants overall and stratified by 
depression status.) 
Non-cardiovascular morbidity was associated with an increased risk for CVD (HR 
95% CI 2.0 ( 1.8,2.6).Those who were depressed and had non-cardiovascular 
morbidity, were at increased risk of CVD; HR 95% CI 2.1 (1.3, 3.4) in analyses 
adjusted for age, gender and SEP versus  those who were depressed and did not 
have non-cardiovascular comorbidity (HR 95% CI 1.5 (1.1, 2.0)). The association 
remained after adjusting for diabetes, hypertension, physical activity, smoking, BMI 
and hazardous alcohol use. (Figure V. Adjusted Hazard ratio for CVD according to 
depression status and non-cardiovascular morbidity, Table 5) 
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5 DISCUSSION  
5.1 MAIN FINDINGS  
This thesis aimed to increase knowledge on the association between depression 
and CVD. The main findings of the thesis are that depression severity (especially 
with concomitant anxious distress) increased the risk for CVD, compared to those 
who were not depressed. Having depression and high level of neuroticism 
increases the risk of CVD compared to those depressed and with low level 
neuroticism. Those who have depression and have high activity COMT Val158Met 
genotype are at increased risk of CVD compared to those depressed with low 
activity Val158Met genotype. We also found that those depressed with non-
cardiovascular morbid conditions were at increased risk of CVD compared to those 
depressed with no non-cardiovascular morbidity.  
5.2 SEVERITY LEVEL OF DEPRESSION AND CVD 
Severity level of depression increased the risk of CVD, although the results do not 
demonstrate a classic dose response effect. Moderately depressed persons 
showed increased risk for CVD compared to mildly and severely depressed. 
Further, those who were depressed and had anxious distress were at higher risk of 
CVD compared to those depressed without anxious distress. 
Previous meta-analyses report about depression as a risk factor for CVD, however 
few studies to date have specifically studied the effect of different levels of severity 
of depression (10, 137). In the Nova Scotia Health Survey in 1995 (n=1302) 
depression was assessed as a quantitative score using the centre for 
epidemiological studies–depression scale. The study  reports  an independent and  
dose response  effect between depression and incident coronary heart disease 
(152). The results of this study are limited by the fact that it was either a small 
population based sample or only those whose records were available in 
administrative healthcare database were included. In analyses of 4538 clinical 
participants, Abramson et al used the same scale and found an increased risk for 
heart failure for those who scored > 16 on the scale(( low (0-7), medium (8-15), 
and high (≥16)) (197). The results of this study is limited by the fact that it included 
only elderly hypertensive people. In 2015, Seldenrijk et al from the Netherlands 
study of depression and anxiety (n=2510) concluded that people with current 
depression have a 2- to 3-fold increased risk of CVD at follow-up of 6 years, and 
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additionally they demonstrated a dose-response association for severity level of 
depression, i.e. the higher the number of symptoms the higher the subsequent 
CVD risk (153). Our study is in line with the above findings, however we did not 
demonstrate a dose response relation between level of severity of depression and 
CVD. The reason for this could be that Seldenrijk used the inventory of depressive 
symptomatology, used only in outpatient settings while we used the major 
depression inventory used in general population for assessment of depression. 
Additionally, our study included a large healthier population-based sample in which 
CVD outcomes were followed through both register and self-reports, while the 
study by Seldenrijk et al included a clinical, less healthy sample with self-reported 
CVD outcomes. It is for this reason that the prevalence of depressed in the PART 
was 14 %, while in the study by Seldenrijk et al the prevalence of depression or 
anxiety was 78 %. The lack of dose response association in our study could 
presumably be also explained by those who had severe psychiatric symptoms 
participated less in this study. This might have resulted also in underestimation of 
the risk (171). Also people with severe depression seek treatment for psychiatric 
disorders more commonly than those with milder forms and hence are more likely 
to be treated (198).  
Studies have been reported on the association of anxiety and CVD. In a 37-year 
follow-up study including 49,321 men from Sweden, anxiety disorders were 
strongly associated with incident CHD and acute myocardial infarction (MI) (199). 
The results of this study is limited by the fact that there was no intermediate follow-
up and anxiety disorders rather than anxious distress was assessed in this study. 
Another 7-year follow-up cohort study of 25,895 Finnish men and women reported 
significant associations of anxiety with elevated risk of CHD (200). The DSM-5 
anxious distress is longitudinally predictive of a worse clinical course, it supersedes 
comorbid DSM-IV-based anxiety disorder diagnoses as a longitudinal predictor 
(201). Our findings that depression with anxious distress increases risk of CVD is 
unique and is predictive of long-term public health and clinical impact on care of 
depressed persons who are at risk of CVD. 
5.3 DEPRESSION, HIGH LEVEL NEUROTICISM AND CVD  
We found that co-existence of depression with high levels of neuroticism increased 
the risk of CVD compared to depressed with low level of neuroticism. Some studies 
have previously shown associations between depression, neuroticism and CVD. 
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Marijnissen et al concluded from a 9-year follow-up study of 2050 participants, 
Longitudinal Aging Study Amsterdam (LASA), that older persons with depression 
and low levels of neuroticism had a higher risk of developing stroke, thus indicating 
a negative interaction in predicting future risk of CVD (202). These results are in 
contrast with our study that suggests a positive interaction between neuroticism 
and depression in predicting CVD. The reasons for this contrast could be that 
outcome assessment for CVD was based on self-reports and medication-based 
diagnoses. This might have resulted in misclassification of outcome thus effecting 
the risk estimates. Secondly LASA had relatively reduced power due to selective 
dropout of persons with missing data. Also, the age group in LASA was older than 
the PART study. A recent study from Sweden (n= 323) reported that depression 
and neuroticism might be contributing to decreased smoking cessation behaviour, 
thus increasing the risk of CVD (203). This lack of smoking cessation behaviour in 
persons with depression and high level of neuroticism could contribute to risk of 
CVD. However, more studies are required to confirm this hypothesis. Our findings 
that those who are depressed and have high levels of neuroticism are at increased 
risk of CVD, is of importance for the clinical management of this group.  
5.4 DEPRESSION, HIGH ACTIVITY COMT VAL 158MET AND CVD 
We found that persons with depression and high activity COMT Val 158Met 
genotype have an increased risk of CVD. The risk was higher in women compared 
to men.  
A previous meta-analysis did not show any association between COMT Val 158Met 
and depression, however the results were limited by substantial heterogeneity 
(204). Previous studies focussing on the combined effect of depression and COMT 
Val 158Met for risk of CVD are non-existent. Most studies talk about the association 
of COMT Val 158Met with CVD, however whether high or low activity COMT Val 
158Met is associated with CVD, is still under debate. A case-control study was 
conducted on 305 young ischemic stroke subjects aged  <50 years from Taiwan 
concluding that COMT Val 158Met polymorphism was significantly associated with 
ischemic stroke among females (205). Hagen et al reported from the Nord-
Trøndelag Health Study (HUNT) (n=2979) that individuals with high activity Val/Val 
genotype had a lower mortality rate due to heart diseases.(206) Although later on 
from the same study, they reported that high COMT activity (Val/Val genotype) was 
overrepresented in Norwegians with systolic hypertension (≥140 mm Hg) (n=2591) 
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(207). Voutilainen et al in the population-based prospective cohort of 792 men, the 
Kuopio Ischemic Heart Disease Risk Factor Study, suggested that low activity 
COMT Val 158Met was associated with a higher risk of acute coronary events (208). 
Similar results have been demonstrated in a Japanese study on 735 men (209). 
We found that those who were depressed and had high activity COMT Val 158Met 
genotype were associated with increased risk of CVD. These findings were 
confirmed by Eriksson et al who reported a protective effect of low activity COMT 
Val 158Met against myocardial infarction in a Swedish and Finnish hypertensive 
sample (n=522) (161). However, these results are limited by the fact that this study 
did not focus on depression. Compared to the HUNT study which included 
nondiabetics and outcome included IHD related mortality, our study included all 
participants’ outcomes being myocardial infraction or stroke. Hence our study did 
not have any selection bias based on disease or gender. 
Our finding of high activity COMT Val 158Met associated with increased risk for CVD 
in women compared to men might be due to following reasons. The gender-based 
difference might be explained by the difference in oestrogen activity between men 
and women and COMT is key in oestrogen metabolism. Thus, the association 
between COMT Val 158Met and CVD in females might reflect altered levels of 
oestrogen and its metabolites in men and women (205). 
5.5 DEPRESSION, NON-CARDIOVASCULAR MORBIDITY AND CVD 
We found that the coexistence of depression and non-cardiovascular morbid 
conditions increased the risk of CVD compared to depressed with no non-
cardiovascular morbid condition. The effect remained after adjusting for adverse 
lifestyle factors.  
Some studies have reported associations between depression and morbidity.(59, 
210) We found only one study focusing on co-existence of depression and 
morbidity on CVD. The study included 6,394 subjects who participated in the First 
National Health and Nutrition Examination Survey (NHANES I) conducted between 
1971 and 1975 and later followed-up between 1982 and 1984 (169). Depression 
and prevalent chronic medical conditions was assessed at baseline and 
participants were followed up for CVD mortality and incident medical conditions. 
The study reported that having more severe depressive symptom increased the 
risk of CVD mortality at follow-up (HR 95%CI 1.5 (1.2, 1.8)), however when 
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considering demographics, lifestyle behaviors, prevalent and incident chronic 
medical conditions, the risk estimates weakened (HR 95% CI 1.1 (0.9, 1.4)). The 
study therefore concluded that the association between depression and CVD 
mortality was partially mediated by prevalent/incident comorbidity. Our study shows 
that depression with coexisting morbidity increases the risk of CVD compared to 
non-depressed or those without non-cardiovascular morbidity. The study by 
Atlantis et al is different from our study with respect to study designs, assessment 
of depression, type of comorbid conditions and CVD outcome. Also, we considered 
non-cardiovascular morbidity as an effect modifier while the former study adjusted 
the results for it. This might have led to underestimation of the risks in the former 
study as adjusting for comorbid might have accounted for most of the association 
between depression and CVD. Also, the former study included the conventional 
risk factors (diabetes, hypertension) in the definition of comorbidity, whereas we 
considered only non-cardiovascular and used incidence of CVD rather than CVD 
mortality.  
Several reasons may contribute to the relation between depression, non-
cardiovascular morbidity and CVD. Firstly poor medication adherence occurs in 
depressed patients which becomes more serious when it is linked to 
noncompliance to medications for a chronic condition (211). Secondly, many 
patients with morbidity do not undergo systematic depression screening in routine 
practice due to time constraints and therefore missing diagnosis of depression in a 
clinic visit might have underestimated the risk (212). Thirdly, the studies are still 
scarce on the temporality of depression and non-cardiovascular morbidity. 
Depression might lead to more chronic physical conditions and it might happen in 
the reverse direction also (213). Also it is still a point of debate whether to treat 
depression first or the chronic illness first, which might result in people with 
depression untreated. 
5.6 POTENTIAL UNDERLYING MECHANISMS FOR THE FINDINGS IN THIS 
THESIS 
Some mechanisms have been proposed discussing the relation between 
depression and CVD. The pathophysiological mechanisms behind depression 
include metabolic, immune-inflammatory, autonomic and hypothalamic pituitary 
axis dysregulation, all of which affect the incidence of CVD (214). Elevated 
depression symptoms are associated with augmented immune cell mobility via 
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leukocyte mobilization in patients suffering from heart failure (215). Depression and 
anxiety results in expedited  progression of atherosclerosis and other 
cardiovascular conditions(216). These augmented immune cell mobility leading to 
expedited atherosclerotic process might be responsible for the link between severe 
levels of depression and CVD. However further studies are required to prove this 
concept. 
 The underlying mechanisms for anxiety has been hypothesized as increased 
cardiovascular reactivity to stress and resting heart rate, decreased heart rate 
variability, bar reflex dysfunction, and greater variability in ventricular repolarization 
(217). Additional mechanisms described in literature suggest that anxious 
depression is associated with distinct neurobiological findings in the hypothalamic 
pituitary axis (218), genetics (219) and chronic inflammatory phenomenon (220). 
Previous studies elucidate underlying biological mechanisms between neuroticism, 
depression and CVD. Čukić and Bates recently published results from a nationally 
representative sample (n=1255) from United States showing that heart rate 
variability is a reliable biomarker for neuroticism (221). They suggested that higher 
neuroticism was associated with reduced heart rate variability equally under rest 
and stress. Reduced heart rate variability has been associated with elevated levels 
of CVD (222). Hence based on our results, we suggest that this reduced heart rate 
variability might be the underlying linking mechanism between neuroticism and 
depression, thus increasing the risk of CVD. Marijnissen et al reported a negative 
interaction between neuroticism and atherosclerosis (223). This means that people 
scoring high on neuroticism and having depression might less vascular risk factors 
while those scoring low on neuroticism might have more vascular risk factors as a 
potential explanation for the increased risk of future stroke (202, 224). In contrast 
our results suggest, that since both depression and neuroticism are independent 
risk factors for CVD, the vascular risk refactors might be shared and hence leads to 
increased CVD. However more studies are required to confirm our findings at 
biological level. 
The function of COMT Val158Met genotype has been under constant debate. One  
common  concept is of  warrior/worrier model by Goldman which talks about 
balance in stress resiliency (Val158 allele) versus cognitive function (Met158 allele) 
(225). The underlying mechanism between COMT Val158Met genotype, depression 
and CVD could be following. Firstly, persons with the at risk allele Val/Val has been 
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reported to have higher heart rate, and increased startle potentiation to aversive 
stimuli relative to the Val/Met or Met/ Met allele (226). This is of course linked to 
catecholamines which have well-known effects on the cardiovascular system, e.g. 
blood pressure regulation (227, 228). This along with depression with anxious 
distress might affect the heart rate variability which is a linking mechanism between 
depression and CVD (229). Secondly, it has been reported that Val/Val women 
carriers have higher cortisol(230) levels compared to Met/Met Allele which might be 
linked to higher blood pressure levels and central obesity.  
The underlying mechanisms shared between depression, non-cardiovascular 
morbidity leading to CVD is largely unknown. Inflammation indicated by circulating 
levels of interleukin-6, C-reactive protein, and fibrinogen may be an important 
biological mechanism (231). Inflammation is also an underlying shared mechanism 
between depression and CVD (232). In depressed people, additional comorbid 
condition might trigger a pathway of inflammation contributing to risk of CVD. Many 
of these pathways are driven by chronic oxidative stress and  a reduction in anti-
ageing molecules (233). 
5.7 METHODOLOGICAL STRENGTHS AND LIMITATIONS  
5.7.1 Design  
The sub studies in this thesis all employed a cohort design. Cohort studies are 
similar to RCTs as they compare outcomes in groups except that the allocation of 
individuals to depressed or non-depressed groups is not random (and there is no 
intervention) (234). The study base was the adult population residing in the 
Stockholm County, all of whom had similar chance of being selected for the study. 
Additionally, large number of participants, and the assessment of exposure are also 
strengths. While we had a large population-based sample of 10341 people, however 
there was lack of power when we did interaction analysis. This is a limitation.  
5.7.2 Selection bias  
Subject selection bias: Factors affecting enrolment of subjects into a cohort study is 
less likely to introduce selection bias as it has to be related to both exposure and 
outcome. Outcome assessment in cohort studies has yet to take place (235). 
Participants in PART was a random sample of participants living in Stockholm 
County, both exposed and unexposed groups were at same likelihood to be selected 
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for the study, thus alleviating the chance of selection bias at the time of recruitment. 
The participation rates in W1 was 53 % is rather low, which is a limitation (171). The 
non-participation analysis revealed that male sex, being below 50 years of age, low 
income, low education, living alone and country of origin outside the Nordic countries 
were strong determinants of non-participation. Additionally, those who had history of 
inpatient psychiatric illness or suffered from severe psychiatric illness were less likely 
to participate.  
In study III, only 41.7% provided DNA samples. Factors associated with public 
negation to consent to DNA bio banking in the PART have been reported. The 
participants thought that giving DNA was not relevant to them. They were 
uncomfortable about giving DNA information for research   used for purposes other 
than the respective study were the reasons for low participation (173).  
Loss to Follow up Bias: The follow-up in the PART study was over a 14-year period 
which was long and increases the chance of lost to follow-up bias. The follow-up rate 
of 61 % in W3 (n=5228) is low. This loss to follow-up might have resulted in 
underestimation of the risks. However, to address this lost to follow-up the outcome 
was assessed through the NPR in all four studies (for this thesis reanalysis of Study I 
was also done using the NPR instead of self-report outcome at W3). Hence the 
chance of lost to follow-up bias was very low and the reported risks for CVD 
therefore have good internal validity. Also, both the exposed and unexposed groups 
were at same likelihood of being followed up for outcome and hence this is also a 
strength of the study, limiting selection bias 
Healthy participant effect: The PART study, since it is based on a population-based 
sample could have a healthy worker effect at the time of selection, as those who 
participated might be the ones who are healthier and were more likely to be 
employed. For example, the ones who had severe psychiatric illness (less healthy) 
were less likely to participate (171). This might have resulted in some degree of 
underestimation of the depression severity. 
5.7.3 Information bias  
Assessment of exposure: The strength is that the exposure of depression was 
assessed using MDI which is a validated, objective scale for assessment of 
depression(176). The MDI was self-administered by the participants, hence it was 
free from any interviewer bias. However, there might be some degree of 
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misclassification due to self-reporting (recall bias) by the participants, however non-
differential of the outcome. This might have underestimated the risk. 
In study  , for the research question of severity of depression and risk of CVD, 
severity level of depression was assessed by using objective cut-offs of MDI into 
mild, moderate and severe (49). Additionally we used anxious distress, which is a 
specifier for severity of depression according to DSM-5(236). Including anxious 
distress as a severity measure for depression and following participants for risk of 
CVD is rather unique and has not been reported before to the best of our knowledge. 
However, one limitation of this study is that we did not have measurements on other 
specifiers of depression like melancholic features, with atypical features and with 
psychotic features.(236) Since PART was a long follow-up, our results are also 
limited by the fact that the status of depression, severity level of depression, level of 
neuroticism  could have changed for participants, thus leading to some degree of 
misclassification of non-differential type, thus underestimating the risks.  
In study II, neuroticism was assessed using the Swedish scale of personality which 
is a validated tool for Swedish population(180). Since this is a validated scale for 
assessment of neuroticism, the chance of misclassification of exposure was minimal. 
However, since the follow-up in PART study is long, there might have been changes 
in the level of neuroticism overtime , and this might have resulted in  misclassification 
of exposure , thus leading to changes in risk estimates. 
We used candidate gene approach for the genetic study (study III), which although is 
now overwhelmed by the rapidly rising genome wide studies, but the chances of 
false positive associations are relatively less in candidate gene approach studies 
(237). Hence this approach minimises the chance of misclassification of exposure.  
The method of assessment of morbidity (study IV), might have resulted is 
misclassification of exposure due to self-reporting bias (recall) by the participants. 
However, this misclassification of exposure is non-differential, i.e. the chance of self-
reporting bias was same in both depressed and non-depressed groups, thus leading 
to underestimation of the risk. Another issue in study IV is that we cannot comment 
on temporality of the relation between depression and non-cardiovascular morbidity 
as both were assessed at the same time. However, as the main outcome of 
importance was the CVD outcome, assessing temporality between depression and 
non-cardiovascular morbidity was of less importance. We also cannot determine 
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whether the recall period for the morbidity assessment was short or long and this is a 
limitation of the study, as the longer the period of recall , the more the chance of 
recall bias(238). However a more objective way of assessing comorbidity using 
scales or diagnostic tests for the large number of comorbid conditions would have 
been cost defective. Another way of measuring morbidity is Charlson comorbidity 
index(239). However we could not use it as it includes morbidity like myocardial 
infraction and stroke, which are not part of non-cardiovascular morbidity.  
Assessment of outcome: The CVD outcome was assessed using the NPR in all 4 
studies which is a reliable measure (125, 240). This alleviates the chance of 
misclassification of outcome. Since the CVD outcomes were taken from NPR, the 
diagnosis of CVD was based on objective clinical diagnostic criteria by the 
physicians/cardiologist. The NPR has excellent coverage hence loss of follow-up at 
outcome assessment was minimal. Also, participants with history of baseline CVD 
were excluded from the analysis to avoid reverse causality and misclassification of 
outcome.  
5.7.4 External Validity and statistical power  
The low participation rate reduced the sample size, resulting in a lack of statistical power 
in studies II, III and IV as there were low numbers of depressed individuals when 
stratifying on level of neuroticism, COMT Val 158 Met and non-cardiovascular morbidity. 
There was also limited external validity of the study as it cannot then be generalized 
to entire population or to those who had severe psychiatric illness (171, 172). 
 Confounders and mediators  
Another strength of the study was that we were able to adjust the analyses for socio-
demographics and CVD risk related lifestyle factors. Our results are limited by the 
fact that we could not adjust for dyslipidaemia which is also an important CVD risk 
factor. This inability of including dyslipidaemia might have overestimated the 
association.   
There were limitations in assessment of SEP, as there was 24 % missing data in it. 
Such large missing data could falsely move the results towards or away from null. 
We then used an alternative method for SEP assessment using daily routine activity 
which reduced the missing information on SEP down to 6 %. There were limitations 
in the measurement of physical inactivity, since a validated physical activity tool was 
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not used, which could have resulted in falsely low or high physical inactivity levels. 
The measurement of alcohol intake was made through a validated tool AUDIT, which 
is a strength of the study resulting in correct measurement of alcohol intake. 
Smoking was assessed using the question of regular, occasional, previous and 
never smoker. While this information was optimal for our study but since we did not 
have information on the pack year history of cigarettes, we might have 
underestimated the effect of smoking on the association. Also, the physical activity 
status and smoking status was only recorded in W2, thus there was missing data for 
these covariates for those who did not participate in W2. This might have led to 
overestimation of the risk. The recording of information on diabetes and 
hypertension might have had some degree of recall bias as this information was 
based on questions thus leading to misclassification bias. We did not have data on 
psychotropic medications which are known to be linked to CVD (241), and hence the 
data could not be adjusted for them, which might have led to overestimation of the 
risk. 
Interaction: Another strength of this thesis was that we tested interaction of 
depression with important concomitant factors like neuroticism, genetics (COM 
Val/Met) and comorbidity for risk of CVD. We used additive interaction mainly as it 
has large public health significance in study II, III and IV(195). Additionally, we also 
calculated synergy index which is a good tool to quantify the interaction between two 
variable and outcome (196). We also checked multiplicative interaction for study II 
and study III, but the effect was not significant, indicating that the magnitude of 
interaction might not be large. 
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6 IMPLICATIONS OF FINDINGS 
6.1 PUBLIC HEALTH SIGNIFICANCE  
Depression is a major public health problem and a large proportion of the affected 
persons go untreated(242). This thesis contributes to a further understanding of the 
etiology of cardiovascular disorders among depressed persons using unique 
population-based data. We found that severity level of depression increased risk of 
CVD, though not in a dose response pattern. The results imply that persons affected 
by depression need identification and control of CVD risk factors and simultaneous 
care and treatment for depression. Also, our study findings suggest that identification 
of at risk genotype like high activity COMT Val 158 Met might be useful to understand 
the risk of CVD for depressed persons. This also coincides with the rising trend of 
precision medicine which is expected to be the new era in treatment of patients 
according to their genetic susceptibility(243). The study on coexistence of non-
cardiovascular morbidity and depression in increasing the risk of CVD is also of 
great importance in today’s era when multi-morbidity is a rapidly rising syndrome 
impacting health, quality of life and health care resources. This interaction of 
depression with non- cardiovascular morbidity is of significant importance as it 
indicates that all patients with comorbidity need to be assessed for depression and 
treated accordingly. It is also important for the general public to understand that they 
might get depressed due to the coexisting morbid condition. Hence treatment for 
both the morbid condition and depression simultaneously should be started. As 
ignoring depression treatment might worsen the outcome of the morbid condition, 
thus leading to worse outcome of the morbidity and also increasing risk for CVD. 
These findings signal the government to implement strategies in primary care for 
earlier identification of both depression, CVD risk factors to prevent CVD  
6.2 CLINICAL SIGNIFICANCE 
The addition of knowledge on the coexistence of depression and neuroticism in 
developing CVD has more clinical implications for physicians and psychiatrist as 
people who are both depressed and have neuroticism are difficult to treat and might 
need earlier and more stringent care than the regular depressed population to 
reduce risk of CVD. This thesis contributes to science in further emphasizing and 
refining the relation of depression and CVD and contributes for consideration of 
depression as a conventional risk factor to CVD in addition to the existing ones.  
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6.3 FUTURE STUDIES 
Future studies in this area can focus on replicating the genetic studies in other 
populations, using scales and more robust methods of identification of comorbid 
conditions in depressed patients and reconfirming the findings of increased risk for 
CVD. The genetic study of COMT Val 158Met is novel for this population in terms of 
the association with cardiovascular diseases. Since this is the first study to report 
this association, more studies need to be replicated in other populations to improve 
external validity of this study. Intervention strategies to treat depression 
(antidepressants v cognitive behavioral therapy) and assessing CVD outcomes.  
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7 CONCLUSION 
This thesis found an association between depression and CVD. We also found that 
severity level of depression and concomitant anxious distress increased the risk of 
CVD, compared to those not depressed. We also found that having depression and 
high levels of neuroticism increased the risk of CVD compared to depressed and 
low-level neuroticism. The existence of depression and high activity COMT Val 
158Met increased their risk of CVD compared to depress and those with low activity 
COMT Val 158Met. Those who had depression and non-cardiovascular morbidity had 
an increased risk of CVD compared to non-depressed and those without non-
cardiovascular morbidity.  
Overall the thesis has contributed to better understanding to the relation between 
depression and CVD. It has also put light on some of the shared risk factors among 
depression and CVD and also how interaction of these risk factors with depression 
increase the risk of CVD. The thesis reconfirms the association of depression and 
CVD and strengthens the concept that more importance is needed for care and 
treatment of depression at mass level.  
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9 APPENDICES 
9.1 APPENDIX A. MAJOR DEPRESSION INVENTORY (MDI): SCORING KEY 
AND INSTRUCTION 
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9.2 APPENDIX B. DSM -5 CRITERIA FOR ANXIOUS DISTRESS AND 
CORRESPONDING QUESTIONS USED FROM SCALES IN MENTAL 
HEALTH IN THE PART STUDY TO ASSESS ANXIOUS DISTRESS 
DSM-5 criteria for 
anxious distress 1 
Scale Question on Symptom  
Feeling keyed up or 
tense. 
Psychological well-being 
scale2  
 
 
 
How many times have you felt calm and 
relaxed during the past week?  
Those who replied “never” or “sometimes” 
were regarded as having anxious distress 
symptom 
Feeling unusually 
restless. 
Major depression 
inventory 3 
 
 
How many times have you felt very restless 
in past 2 weeks? 
Those who answered “all the time”, “most of 
the time” or “slightly more than half of the 
time” were regarded as having anxious 
distress symptom  
Difficulty 
concentrating 
because of worry. 
Major depression 
inventory  
How many times have you had difficulty in 
concentrating in past 2 weeks? 
Those who answered “all the time”, “most of 
the time” or “slightly more than half of the 
time”  were regarded as having anxious 
distress symptom  
Fear that something 
awful may happen. 
Symptoms of anxiety 
during the past 30 days.4  
 
How much in the past 1 month have you 
experienced fear of dying?  
Those who answered “much” or 
“very much” were regarded as having 
anxious distress symptom  
Feeling that the 
individual might lose 
control of himself or 
herself. 
Symptoms of anxiety 
during the past 30 days  
How much in the past 1 month have you had 
fear of losing control?  
Those who answered “much” or “very much” 
were regarded as  having anxious distress 
symptom  
 
1 Anxious distress is defined as the presence of at least two of the following symptoms during the majority of 
days of a major depressive episode or persistent depressive disorder (dysthymia). In the present study severity 
was classified as; mild: two symptoms, moderate: three symptoms, moderate-severe: four or five symptoms; 
and severe: four or five symptoms and with motor agitation. (http://dsm.psychiatryonline.org//, doi: 10th April 
2015) 
2 Bech, P., Gudex, C., Staehr Johansen, K. (1996). The WHO (Ten) Well-Being Index: Validation in Diabetes. 
Psychother Psychosom, 65, 183-190. 
3 Bech, P., Wermuth, L. (1998). Applicability and validity of the Major Depression Inventory in patients with 
Parkinson´s disease. Nord J Psychiatry, 52, 305-309 
.4 Sheehan, D. V. (1983). The anxiety disease (pp 124-129). New York: Charles Scribners Sons  
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9.3 APPENDIX C. SWEDISH SCALE OF PERSONALITY REFLECTING 
NEUROTICISM; MEAN AND T SCORE  
Scale  Question 
number 
in SSP 
Question  Mean (SD) 
score of 
individual 
questions1 
Mean(SD) 
score of 
scale  
Mean 
(SD) t-
score of 
scale 3 
Somatic Trait 
Anxiety (STA) 
     
 1 Quite often, I found 
myself without reason 
clenching my jaw. 
1.8 (0.97) 1.7 (0.5) 47.9 
(9.7) 
 14 I often feel restless, as 
if I wanted something 
without knowing what. 
2.0 (0.9) 
 27 I often feel stiff and 
tense the body 
2.0 (0.9) 
 40 Sometimes, my heart 
thumps hard or beat 
irregularly without 
tangible reason. 
1.5 (0.8) 
 53 I can suddenly start 
sweating for no 
particular reason. 
1.5 (0.8) 
 66 I jerk violently to 
unexpected sounds. 
1.9 (0.9) 
 79 Sometimes I get a 
feeling of not getting 
enough air to breathe. 
1.4 (0.8) 
Stress 
Susceptibility(SS) 
     
 3 I can too easily get 
tired and stressed. 
2.2 (0.8) 2.0 (0.4) 51.0 
(8.1) 
 -162 I can easily be 
disturbed when I'm 
doing a job. 
2.0 (0.7) 
 29 In order to get anything 
done, I have to 
consume more power 
than most. 
1.5 (0.7) 
 -42 I tend to concentrate 
even if the 
surroundings are 
distracting 
2.2 (0.7) 
 55 I get easily stressed 
when I am asked to 
speed up my work. 
2.0 (0.8) 
 -68 I feel calm and 
confident even if I have 
to face new challenges. 
2.2 (0.7) 
 81 I find that I have less 
energy than most of my 
acquaintances. 
1.6 (0.8) 
Embitterment(E)      
 9 I have had it quite 
difficult in life 
1.8 (0.8) 1.6 (0.4) 
  
46.5 
(9.9) 
 22 I never seem to be able 
to avoid getting into 
jams. 
0.6 (1.3) 
 35 I have often got into 
trouble, even though it 
was not my fault. 
1.3 (0.6) 
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 48 It looks as if I would 
never get any chance 
to get anywhere in life. 
1.5 (0.7) 
 61 I seem to more often 
than others do things 
that I later regret 
1.4 (0.6) 
 74 It happened that I 
envied people who 
have been lucky in life 
2.1 (0.9) 
 87 I feel often like I did 
something bad or 
wrong. 
1.5 (0.7) 
1 Each item is given as a statement with a four-point response format, ranging from 1 to 4, 1 point for the 
“disagree” and so on to 4 points for the “agree”. 
2 Minus in front of the question number means the scoring was reversed. This applies to the item 7, 16, 30, 38, 
42, 68, 85, and 86 
3 t-scores have been calculated according to Gustavsson, J.P., et al., Swedish universities Scales of 
Personality (SSP): construction, internal consistency and normative data. Acta Psychiatr Scand, 2000: 102(3). 
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